Search Results - "Keppens, Cleo"

Causes behind error rates for predictive biomarker testing: the utility of sending post-EQA surveys by Keppens, Cleo, Schuuring, Ed, Dequeker, Elisabeth M. C.

“…External quality assessment (EQA) schemes assess the performance of predictive biomarker testing in lung and colorectal cancer and have previously demonstrated…”
Get full text

PD-L1 immunohistochemistry in non-small-cell lung cancer: unraveling differences in staining concordance and interpretation by Keppens, Cleo, Dequeker, Elisabeth MC, Pauwels, Patrick, Ryska, Ales, ‘t Hart, Nils, von der Thüsen, Jan H

“…Programmed death ligand 1 (PD-L1) immunohistochemistry (IHC) is accepted as a predictive biomarker for the selection of immune checkpoint inhibitors. We…”
Get full text

International pilot external quality assessment scheme for analysis and reporting of circulating tumour DNA by Keppens, Cleo, Dequeker, Elisabeth M C, Patton, Simon J, Normanno, Nicola, Fenizia, Francesca, Butler, Rachel, Cheetham, Melanie, Fairley, Jennifer A, Williams, Hannah, Hall, Jacqueline A, Schuuring, Ed, Deans, Zandra C

“…Molecular analysis of circulating tumour DNA (ctDNA) is becoming increasingly important in clinical treatment decisions. A pilot External Quality Assessment…”
Get full text

Evaluation of a worldwide EQA scheme for complex clonality analysis of clinical lymphoproliferative cases demonstrates a learning effect by Keppens, Cleo, Boone, Elke, Gameiro, Paula, Tack, Véronique, Moreau, Elisabeth, Hodges, Elizabeth, Evans, Paul, Brüggemann, Monika, Carter, Ian, Lenze, Dido, Sarasquete, Maria Eugenia, Möbs, Markus, Liu, Hongxiang, Dequeker, Elisabeth M. C., Groenen, Patricia J. T. A.

“…Clonality analysis of immunoglobulin (IG) or T-cell receptor (TR) gene rearrangements is routine practice to assist diagnosis of lymphoid malignancies…”
Get full text

Sensitive detection methods are key to identify secondary EGFR c.2369C>T p.(Thr790Met) in non-small cell lung cancer tissue samples by Keppens, Cleo, Dequeker, Elisabeth M C, Rouleau, Etienne, 't Hart, Nils, Bubendorf, Lukas, Dufraing, Kelly, Garrec, Céline, Guéguen, Paul, Lamy, Aude, Marchetti, Antonio, Pauwels, Patrick, Ryska, Ales, Tack, Véronique, Tornillo, Luigi, Van Casteren, Kaat, von der Thüsen, Jan H, Zwaenepoel, Karen, Lissenberg-Witte, Birgit, Thunnissen, Erik, Schuuring, Ed

“…Correct identification of the EGFR c.2369C>T p.(Thr790Met) variant is key to decide on a targeted therapeutic strategy for patients with acquired EGFR TKI…”
Get full text

Describing the Reportable Range Is Important for Reliable Treatment Decisions by Tack, Véronique, Spans, Lien, Schuuring, Ed, Keppens, Cleo, Zwaenepoel, Karen, Pauwels, Patrick, Van Houdt, Jeroen, Dequeker, Elisabeth M.C.

“…Because interpretation of next-generation sequencing (NGS) data remains challenging, optimization of the NGS process is needed to obtain correct sequencing…”
Get full text

Managing Deviating EQA Results: A Survey to Assess the Corrective and Preventive Actions of Medical Laboratories Testing for Oncological Biomarkers by Keppens, Cleo, Schuuring, Ed, Dequeker, Elisabeth Mc

“…Laboratories testing predictive biomarkers in lung and colorectal cancer are advised to participate in external quality assessment (EQA) schemes. This study…”
Get full text

External Quality Assessment Schemes for Biomarker Testing in Oncology by Van Casteren, Kaat, Keppens, Cleo, Schuuring, Ed, Deans, Zandra C., Normanno, Nicola, Patton, Simon J., Dequeker, Elisabeth M.C.

“…Liquid biopsies have emerged as a useful addition to tissue biopsies in molecular pathology. Literature has shown lower laboratory performances when a new…”
Get full text

IQN path ASBL report from the first European cfDNA consensus meeting: expert opinion on the minimal requirements for clinical ctDNA testing by Deans, Zandra C., Butler, Rachel, Cheetham, Melanie, Dequeker, Elisabeth M. C., Fairley, Jennifer A., Fenizia, Francesca, Hall, Jacqueline A., Keppens, Cleo, Normanno, Nicola, Schuuring, Ed, Patton, Simon J.

“…Liquid biopsy testing is a new laboratory-based method that detects tumour mutations in circulating free DNA (cfDNA) derived from minimally invasive blood…”
Get full text

Late age increase in soluble amyloid-beta levels in the APP23 mouse model despite steady-state levels of amyloid-beta-producing proteins by Janssen, Leen, Keppens, Cleo, De Deyn, Peter P., Van Dam, Debby

“…Age is considered the most important risk factor for Alzheimer's disease. Soluble amyloid-beta (Aβ) has been implicated as the primary neurotoxic agent in…”
Get full text

Accreditation, setting and experience as indicators to assure quality in oncology biomarker testing laboratories by Tack, Véronique, Schuuring, Ed, Keppens, Cleo, Hart, Nils ‘t, Pauwels, Patrick, van Krieken, Han, Dequeker, Elisabeth M.C.

“…Background Predictive biomarkers allow clinicians to optimise cancer treatment decisions. Therefore, molecular biomarker test results need to be accurate and…”
Get full text

Describing the Reportable Range Is Important for Reliable Treatment Decisions: A Multiple Laboratory Study for Molecular Tumor Profiling Using Next-Generation Sequencing by Tack, Véronique, Spans, Lien, Schuuring, Ed, Keppens, Cleo, Zwaenepoel, Karen, Pauwels, Patrick, Van Houdt, Jeroen, Dequeker, Elisabeth M C

“…Because interpretation of next-generation sequencing (NGS) data remains challenging, optimization of the NGS process is needed to obtain correct sequencing…”
Get full text

Staining Performance of ALK and ROS1 Immunohistochemistry and Influence on Interpretation in Non–Small-Cell Lung Cancer by Keppens, Cleo, von der Thüsen, Jan, Pauwels, Patrick, Ryska, Ales, ’t Hart, Nils, Schuuring, Ed, Miller, Keith, Thunnissen, Erik, Zwaenepoel, Karen, Dequeker, Elisabeth M.C.

“…Selection of non–small-cell lung cancer patients for treatment relies on the detection of expression of anaplastic lymphoma kinase (ALK) and ROS proto-oncogene…”
Get full text

Review of the implementation of plasma ctDNA testing on behalf of IQN Path ASBL: a perspective from an EQA providers’ survey by Deans, Zandra C., Williams, Hannah, Dequeker, Elisabeth M. C., Keppens, Cleo, Normanno, Nicola, Schuuring, Ed, Patton, Simon J., Cheetham, Melanie, Butler, Rachel, Hall, Jacqueline A.

Get full text

External Quality Assessment Schemes for Biomarker Testing in Oncology: Comparison of Performance between Formalin-Fixed, Paraffin-Embedded-Tissue and Cell-Free Tumor DNA in Plasma by Van Casteren, Kaat, Keppens, Cleo, Schuuring, Ed, Deans, Zandra C, Normanno, Nicola, Patton, Simon J, Dequeker, Elisabeth M C

“…Liquid biopsies have emerged as a useful addition to tissue biopsies in molecular pathology. Literature has shown lower laboratory performances when a new…”
Get full text

Variation in nomenclature of somatic variants for selection of oncological therapies: Can we reach a consensus soon? by Keppens, Cleo, Tack, Véronique, Dufraing, Kelly, Rouleau, Etienne, Ligtenberg, Marjolijn J. L., Schuuring, Ed, Dequeker, Elisabeth M. C.

“…A standardized nomenclature for reporting oncology biomarker variants is key to avoid misinterpretation of results and unambiguous registration in clinical…”
Get full text

European follow-up of incorrect biomarker results for colorectal cancer demonstrates the importance of quality improvement projects by Keppens, Cleo, Dufraing, Kelly, van Krieken, Han J., Siebers, Albert G., Kafatos, George, Lowe, Kimberly, Demonty, Gaston, Dequeker, Elisabeth M. C.

“…Biomarker analysis for colorectal cancer has been shown to be reliable in Europe with 97% of samples tested by EQA participants to be correctly classified…”
Get full text

Detection of EGFR Variants in Plasma: A Multilaboratory Comparison of a Real-Time PCR EGFR Mutation Test in Europe by Keppens, Cleo, Palma, John F, Das, Partha M, Scudder, Sidney, Wen, Wei, Normanno, Nicola, van Krieken, J Han, Sacco, Alessandra, Fenizia, Francesca, Gonzalez de Castro, David, Hönigschnabl, Selma, Kern, Izidor, Lopez-Rios, Fernando, Lozano, Maria D, Marchetti, Antonio, Halfon, Philippe, Schuuring, Ed, Setinek, Ulrike, Sorensen, Boe, Taniere, Phillipe, Tiemann, Markus, Vosmikova, Hana, Dequeker, Elisabeth M C

“…Molecular testing of EGFR is required to predict the response likelihood to targeted therapy in non-small cell lung cancer. Analysis of circulating tumor DNA…”
Get full text

Incidents in Molecular Pathology: Frequency and Causes During Routine Testing by Keppens, Cleo, Van Royen, Yann, Brysse, Anne, Cotteret, Sophie, Høgdall, Estrid, Kuhlmann, Tine Plato, O'Sullivan, Brendan, Pauwels, Patrick, Pauwels, Siegrid, Rot, Mitja, Vanderheyden, Nancy, Van Hee, Ilse, Dequeker, Elisabeth Mc

“…Errors in laboratory medicine could compromise patient safety. Good laboratory practice includes identifying and managing nonconformities in the total test…”
Get full text

Sensitive detection methods are key to identify secondary EGFR c.2369CT p.(Thr790Met) in non-small cell lung cancer tissue samples by Keppens, Cleo, Dequeker, Elisabeth M. C, Rouleau, Etienne, t Hart, Nils, Bubendorf, Lukas, Dufraing, Kelly, Garrec, Céline, Guéguen, Paul, Lamy, Aude, Marchetti, Antonio, Pauwels, Patrick, Ryska, Ales, Tack, Véronique, Tornillo, Luigi, Van Casteren, Kaat, von der Thüsen, Jan H, Zwaenepoel, Karen, Lissenberg-Witte, Birgit, Thunnissen, Erik, Schuuring, Ed

“…Background Correct identification of the EGFR c.2369C>T p.(Thr790Met) variant is key to decide on a targeted therapeutic strategy for patients with acquired…”
Get full text